• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Quest Diagnostics (NY: DGX )

    153.10 +1.58 (+1.04%)
    Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Quest Diagnostics

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
    Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. 
    Via News Direct
    Exposures Product Safety
    Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
    U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
    Via Benzinga
    Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
    Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval 
    From Mainz BioMed NV
    Via GlobeNewswire
    The Analyst Landscape: 8 Takes On Quest Diagnostics
    Via Benzinga
    (DGX) - Analyzing Quest Diagnostics's Short Interest
    Via Benzinga
    Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Guardant Health Stock Sees RS Rating Jump To 83
    On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
    Via Investor's Business Daily
    Navigating Earnings Season: Weather Any Storm
    The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and... 
    Via Talk Markets
    How Is The Market Feeling About Quest Diagnostics?
    Via Benzinga
    What Analysts Are Saying About Quest Diagnostics Stock
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
    Via Benzinga
    Earnings Preview: Quest Diagnostics
    Via Benzinga
    Looking Into Quest Diagnostics's Recent Short Interest
    Via Benzinga
    Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
    Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
    Via Benzinga
    Topics Government
    Exposures Political
    Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
    LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather. 
    Via Benzinga
    Topics Earnings
    Exposures Financial
    This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
    Via Benzinga
    Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Decoding 7 Analyst Evaluations For Quest Diagnostics
    Via Benzinga
    What Analysts Are Saying About Quest Diagnostics Stock
    Via Benzinga
    Uncovering Dividend Opportunities with NYSE:DGX.
    Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. 
    Via Chartmill
    Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
    Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins. 
    Via Benzinga
    Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
    Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
    Via Benzinga
    8 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
    LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
    Via Benzinga
    5 Analysts Assess Quest Diagnostics: What You Need To Know
    Via Benzinga
    Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
    Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... 
    Via Benzinga
    Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
    Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc. 
    Via Benzinga
    DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
    DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.